[go: up one dir, main page]

EP1201660B1 - Modulateurs des récepteurs glucocorticoides - Google Patents

Modulateurs des récepteurs glucocorticoides Download PDF

Info

Publication number
EP1201660B1
EP1201660B1 EP01308789A EP01308789A EP1201660B1 EP 1201660 B1 EP1201660 B1 EP 1201660B1 EP 01308789 A EP01308789 A EP 01308789A EP 01308789 A EP01308789 A EP 01308789A EP 1201660 B1 EP1201660 B1 EP 1201660B1
Authority
EP
European Patent Office
Prior art keywords
compound
octahydro
oxadiazol
ethyl
phenylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01308789A
Other languages
German (de)
English (en)
Other versions
EP1201660A1 (fr
Inventor
Kevin Kun-Chin c/o Pfizer Global Res. & Dev. Liu
Bradley P. c/o Pfizer Global Res. & Dev. Morgan
Ralph Pelton Pfizer Global Res. & Dev. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of EP1201660A1 publication Critical patent/EP1201660A1/fr
Application granted granted Critical
Publication of EP1201660B1 publication Critical patent/EP1201660B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention provides non-steroidal compounds which are selective modulators (e.g., agonists, partial agonists and/or antagonists) of a steroid receptor, specifically, the glucocorticoid receptor.
  • the present invention also provides pharmaceutical compositions containing these compounds and their use for the manufacture of a medicament to treat animals requiring glucocorticoid receptor agonist and/or antagonist therapy.
  • Glucocorticoid receptor modulators are useful to treat diseases such as obesity, diabetes, inflammation and others as described below.
  • the present invention also provides processes for preparing these compounds.
  • Nuclear receptors are classically defined as a family of ligand dependent transcription factors that are activated in response to ligand binding (R.M. Evans, 240 Science, 889 (1988)). Members of this family include the following receptors: glucocorticoid, mineralocorticoid, androgen, progesterone and estrogen. Naturally occurring ligands to these receptors are low molecular weight molecules that play an important role in health and in many diseases. Excesses or deficiencies of these ligands can have profound physiological consequences. As an example, glucocorticoid excess results in Cushing's Syndrome, while glucocorticoid insufficiency results in Addison's Disease.
  • the glucocorticoid receptor is present in glucocorticoid responsive cells where it resides in the cytosol in an inactive state until it is stimulated by an agonist. Upon stimulation the glucocorticoid receptor translocates to the cell nucleus where it specifically interacts with DNA and/or protein(s) and regulates transcription in a glucocorticoid responsive manner.
  • proteins that interact with the glucocorticoid receptor are the transcription factors, API and NF ⁇ -B. Such interactions result in inhibition of API- and NF ⁇ -B- mediated transcription and are believed to be responsible for some of the anti-inflammatory activity of endogenously administered glucocorticoids.
  • glucocorticoids may also exert physiologic effects independent of nuclear transcription.
  • Biologically relevant glucocorticoid receptor agonists include cortisol and corticosterone. Many synthetic glucocorticoid receptor agonists exist including dexamethasone, prednisone and prednisilone.
  • glucocorticoid receptor antagonists bind to the receptor and prevent glucocorticoid receptor agonists from binding and eliciting GR mediated events, including transcription.
  • RU486 is an example of a non-selective glucocorticoid receptor antagonist.
  • U.S. Patent No. 3,683,091 discloses phenanthrene compounds, specifically certain di-7-hydroxy or methyl-2,3,4,4a,9,10-hexahydrophenanthren-2-one and 4a-alkyl derivatives, hydrogenated derivatives, functional derivatives and optically active isomers thereof useful as specific anti-acne agents.
  • Japanese Patent Application, Publication No. 45014056 published 20 May 1970, discloses the manufacture of 1,2,3,4,9,10,11 ⁇ ,12-octahydro-7-methoxy-12 ⁇ -butylphenanthren-2 ⁇ -ol and certain of its derivatives useful as antiandrogenic and antianabolic drugs.
  • Japanese Patent Application, Publication No. 6-263688 published 20 September 1994, discloses certain phenanthrene derivatives which are interleukin-1 (IL-1) inhibitors. It also discloses their preparation and certain intermediates thereto.
  • International Patent Application Publication No. WO 95/10266 published 20 April 1995, discloses the preparation and formulation of certain phenanthrene derivatives as nitrogen monoxide synthesis inhibitors.
  • Japanese Patent Application, Publication No. 45-36500 published 20 November 1970, discloses a method of making certain optically active phenanthrene derivatives which are useful as antiandrogenic agents.
  • European Patent Application, Publication No. 0 188 396, published 23 July 1986, discloses certain substituted steroid compounds, certain process and intermediates for preparing them, their use and pharmaceutical compositions containing them. These compounds are disclosed to possess antiglucocorticoid activity, and some of them have glucocorticoid activity.
  • Japanese Patent 09052899 discloses certain diterpene or triterpene derivatives which are leukotriene antagonists obtained by extraction from Tripterygium wilfordii for therapeutic use.
  • U.S. Patent No. 5,696,127 discloses certain nonsteroidal compounds, such as 5H-chromeno[3,4-f]quinolines, which are selective modulators of steroid receptors.
  • U.S. Patent No. 5,767,113 discloses certain synthetic steroid compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance.
  • NIDDM non-insulin dependent Diabetes Mellitus
  • Treatment agents such as certain steroid compounds having both glucocorticoid receptor type I agonist activity and glucocorticoid receptor type II antagonist activity are also disclosed.
  • Glucocorticoid receptor modulators are disclosed in International patent application PCT/IB00/00366, filed March 27, 2000 (WO 00/66522, published 9 November 2000), and assigned to the assignee hereof.
  • R 1 is a) -(C 1 -C 6 )alkyl optionally substituted with -CF 3 , b) -C ⁇ C-CH 3 , c) -C ⁇ C-Cl, d) -C ⁇ C-CF 3 , e) -CH 2 O(C 1 -C 4 )alkyl optionally substituted with -CF 3 or f) -CF 3 ;
  • R 2 is a) -(C 1 -C 5 )alkyl, b) -(C 2 -C 5 )alkenyl or c) -phenyl optionally substituted with one of the following: -OH, -NR 8 R 9 , -NR 8 -C(O)-(C 1 -C 4 )alkyl, -CN, -Z-het,-O-(C 1 -C 3 )alkyl-C(O)-NR 8
  • the present invention provides compounds of Formula II or a pharmaceutically acceptable salt of said compound ; wherein R 1 is a) -(C 1 -C 6 )alkyl optionally substituted with-CF 3 , b) -C ⁇ C-CH 3 , c) -CF 3 or d) -CH 2 O(C 2 -C 4 )alkyl; and n is one or two.
  • the present invention provides such compounds wherein R 1 is a) -CH 2 CH 2 CH 3 , b) -C ⁇ C-CH 3 or c) -CF 3 ; and n is one. More particularly, the present invention provides such compounds wherein R 1 is a) -CH 2 CH 2 CH 3 or b) CF 3 .
  • the present invention provides such compounds wherein R 3 is -(C 1 -C 2 )alkyl-NR 4 R 5 ; and R 4 and R 5 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl. Even more particularly, the present invention provides such compounds wherein R 3 is -(C 1 -C 2 )alkyl-NR 4 R 5 ; and R 4 and R 5 are each independently a) methyl or b) ethyl.
  • R 3 is -(C 0 -C 2 )alkyl-het; het is a) morpholinyl, b) pyrrolidinyl, c) piperidinyl, d) piperazinyl, e) hexahydro-azepinyl, f) azabicyclo[2.2.2]oct-3-yl, g) azabicyclo[3.2.1]oct-3-yl, h) 3,6-diazabicyclo[3.1.1]heptyl, i) 2,5-diazabicyclo[2.2.1]heptyl, j) 1,2,5,6-tetrahydro-pyridinyl, k) azetidinyl, l) 1,4-diazabicyclo[3.2.2]nonanyl, m) 3,6-diazabicyclo[3.2.2]nonanyl, n) octa
  • R 3 is -(C 0 -C 2 )alkyl-het; het is a) morpholinyl, b) piperidinyl, c) 1,2,5,6-tetrahydro-pyridinyl, d) azetidinyl or e) pyrrolidinyl; the above het groups are optionally substituted with one or two R 6 ; R 6 for each occurrence is independently a) methyl or b) ethyl.
  • the present invention also provides compounds of Formula I wherein R 1 is a) -CH 2 CH 2 CH 3 , b) -C ⁇ C-CH 3 or c) -CF 3 ; R 2 is a) methyl, b) ethyl, c) propyl, d) ethenyl or e) propenyl; R 3 is -(C 1 -C 2 )alkyl-NR 4 R 5 ; R 4 and R 5 are each independently a) methyl or b) ethyl; and n is one.
  • the present invention also provides compounds of Formula I wherein R 1 is a) -CH 2 CH 2 CH 3 , b) -C ⁇ C-CH 3 or c) -CF 3 ; R 2 is a) methyl, b) ethyl, c) propyl, d) ethenyl or e) propenyl; R 3 is -(C 0 -C 2 )alkyl-het; het is a) morpholinyl, b) piperidinyl or c) pyrrolidinyl; the above het groups are optionally substituted with one or two R 6 ; R 6 for each occurrence is independently a) methyl or b) ethyl; and n is one.
  • the present invention also provides compounds which are useful for the treatment of a glucocorticoid receptor-mediated disease or condition in a mammal, which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt of said compound. More particularly, the compounds are useful for the treatment of the glucocorticoid receptor-mediated disease or condition selected from the group consisting of obesity, diabetes, depression, anxiety and neurodegeneration. Even more particularly, the compounds are useful for the treatment of obesity. Even more particularly, the compounds are useful for treatments which further comprise administering a ⁇ 3 agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist.
  • the compounds are useful for treatments wherein the eating behavior modifying agent is orlistat or sibutramine.
  • the present invention provides compounds useful for the treatment of diabetes.
  • the compounds are useful for treatments which further comprise administering an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, insulin, a sulfonylurea, glipizide, glyburide, or chlorpropamide.
  • the compounds are useful for treatments wherein the glucocorticoid receptor-mediated disease is an inflammatory disease.
  • the present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt of said compound; and a pharmaceutically acceptable carrier, vehicle or diluent.
  • the present invention also provides pharmaceutical combination compositions comprising: a therapeutically effective amount of a composition comprising:
  • kits comprising:
  • the present invention also provides methods for inducing weight loss in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound.
  • the present invention also provides pharmaceutical combination compositions comprising: a therapeutically effective amount of a composition comprising:
  • the present invention also provides compounds which are useful for the treatment of an inflammatory disease in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt of said compound.
  • the present invention provides compounds useful for treatments wherein the inflammatory disease is selected from the group consisting of arthritis, asthma, rhinitis and immunomodulation.
  • the present invention provides processes for preparing a compound of Formula II wherein R 1 is a) -(C 1 -C 3 )alkyl, b) -C ⁇ C-CH 3 , c) -CF 3 or d) -CH 2 O(C 2 -C 4 )alkyl; Z for each occurrence is independently -(C 0 -C 4 )alkyl; R 3 is a) -(C 1 -C 6 )alkyl, b) Z-NR 4 R 5 or c) -Z-het; R 4 and R 5 are each independently a) hydrogen or b) -(C 1 -C 3 )alkyl; het is an optionally substituted 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzen
  • the present invention provides such processes wherein in step a) the leaving group is tosylate or mesylate, the base is Et 3 N and the aprotic solvent is THF or CH 3 CN. More particularly, the present invention provides such processes wherein in step b) the protic solvent is ethanol or methanol and the base is K 2 CO 3 . More particularly, the present invention provides such processes wherein in step c) the acetylating agent is carboxylic acid chloride, anhydride or alkyl ester, the base is pyridine and the aprotic solvent is DMF.
  • the present invention provides compounds of formula II-B wherein n is one to three; and R 1 is a) -(C 1 -C 3 )alkyl, b) -C ⁇ C-CH 3 , c) -CF 3 or d) -CH 2 O(C 2 -C 4 )alkyl.
  • the present invention provides compounds of formula II-C wherein n is one to three; and R 1 is a) -(C 1 -C 3 )alkyl, b) -C ⁇ C-CH 3 , c) -CF 3 or d) -CH 2 O(C 2 -C 4 )alkyl.
  • the compounds of the present invention are named according to the IUPAC or CAS nomenclature system.
  • C i -C j indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive.
  • C 1 -C 3 alkyl refers to alkyl of one to three carbon atoms, inclusive, or methyl, ethyl, propyl and isopropyl, and all isomeric forms and straight and branched forms thereof.
  • alkyl of one to six carbon atoms, inclusive are methyl, ethyl, propyl, butyl, pentyl and hexyl, and all isomeric forms and straight and branched thereof.
  • alkenyl of two to five carbon atoms, inclusive are ethenyl, propenyl, butenyl, pentenyl and hexenyl, and all isomeric forms and straight and branched forms thereof.
  • alkynyl of two to six carbon atoms, inclusive are ethynyl, propynyl, butynyl, pentynyl and hexynyl, and all isomeric forms and straight and branched forms thereof.
  • cycloalkyl, cycloalkenyl and cycloalkynyl refer to cyclic forms of alkyl, alkenyl and alkynyl, respectively.
  • exemplary (C 3 -C 8 )cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • halo includes chloro, bromo, iodo and fluoro.
  • aryl refers to an optionally substituted six-membered aromatic ring, including polyaromatic rings. Examples of aryl include phenyl, naphthyl and biphenyl.
  • heterocyclic ring refers to an optionally substituted 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring.
  • the heterocyclic ring, including each heteroatom can be unsubstituted or substituted with one to three independent substituents, as chemically feasible.
  • Exemplary five-membered rings are furyl, thienyl, 2H-pyrrolyl, 3H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl, oxazolyl, thiazolyl, imidazolyl, 2H-imidazolyl, 2-imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2-dithiolyl, 1,3-dithiolyl, 3H-1,2-oxathiolyl, 1,2,3-oxadizaolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,4-trizaolyl, 1,3,
  • Exemplary six-membered rings are 2H-pyranyl, 4H-pyranyl, pyridinyl, piperidinyl, 1,2-dioxinyl, 1,3-dioxinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-trizainyl, 1,3,5-trithianyl, 4H-1,2-oxazinyl, 2H-1,3-oxazinyl, 6H-1,3-oxazinyl, 6H-1,2-oxazinyl, 1,4-oxazinyl, 2H-1,2-oxazinyl, 4H-1,4-oxazinyl, 12,5-oxathiazinyl,
  • Exemplary seven-membered rings are azepinyl, oxepinyl, thiepinyl and 1,2,4-diazepinyl.
  • Exemplary eight membered rings are azacyclooctyl, azacyclooctenyl, azacyclooctadienyl, oxacyclooctyl, oxacyclooctenyl, oxacyclooctadienyl, thiocyclooctyl, thiocyclooctenyl and thiocyclooctadienyl.
  • Exemplary bicyclic rings consisting of combinations of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen are indolizinyl, indolyl, isoindolyl, 3H-indolyl, 1 H-isoindolyl, indolinyl, cyclopenta(b)pyridinyl, pyrano(3,4-b)pyrrolyl, benzofuryl, isobenzofuryl, benzo(b)thienyl, benzo(c)thienyl, 1H-indazolyl, indoxazinyl, benzoxazolyl, anthranilyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolin
  • mammals is meant to refer to all mammals, including, for example, primates such as humans and monkeys. Examples of other mammals included herein are rabbits, dogs, cats, cattle, goats, sheep and horses. Preferably, the mammal is a female or male human.
  • treating includes preventative (e.g., prophylactic) and palliative treatment.
  • terapéuticaally effective amount means an amount of a compound of the present invention that ameliorates, attenuates or eliminates a particular disease or condition or prevents or delays the onset of a particular disease or condition.
  • compound(s) of the present invention or “compound(s) of Formula I” shall at all times be understood to include all active forms of such compounds, including, for example, the free form thereof, e.g., the free acid or base form, and also, all prodrugs, polymorphs, hydrates, solvates and tautomers, and all pharmaceutically acceptable salts, unless specifically stated otherwise. It will also be appreciated that suitable active metabolites of such compounds are within the scope of the present invention.
  • pharmaceutically acceptable it is meant the carrier, vehicle, diluent, excipient and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
  • the compound of formula A-1 (prepared as described in Org. Syn. 1971, 51, 109-112) (R x is halogen or methyl ether) is reacted with a nitrogen-containing base, such as pyrrolidine, piperidine or morpholine, at a refluxing temperature in an aprotic solvent such as toluene, benzene, dichloromethane or dioxane.
  • a nitrogen-containing base such as pyrrolidine, piperidine or morpholine
  • R 2 is (C 1 -C 5 )alkyl straight chain, isopropyl, t-butyl, phenyl or is as described in the Summary above, and X 1 is a leaving group (see, e.g., Francis A. Carey, in Advanced Organic Chemistry , 2 nd ed., Part A, Chapter 5.6, 1984) in toluene, dioxane, methanol, ethanol, isopropanol, DMF, DMSO or THF to give the compound of formula A-2.
  • Typical alkylating agents are primary, secondary, benzylic or allylic halides and are preferably alkyl bromides or alkyl iodides.
  • the compound of formula A-1 is converted to its anion with a strong base, such as sodium hydride, sodium methoxide, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, potassium t-butoxide or others, in an aprotic solvent, such as dimethylformamide (DMF) or tetrahydrofuran (THF).
  • a strong base such as sodium hydride, sodium methoxide, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, potassium t-butoxide or others
  • an aprotic solvent such as dimethylformamide (DMF) or tetrahydrofuran (THF).
  • DMF dimethylformamide
  • THF tetrahydrofuran
  • the compound of formula A-1 is reacted with R 2 CH 2 -CHO and a base such as pyrrolidine or an acid such as acetic acid or hydrochloric acid in a solvent such as toluene, benzene, methanol or ethanol.
  • a base such as pyrrolidine or an acid such as acetic acid or hydrochloric acid
  • a solvent such as toluene, benzene, methanol or ethanol.
  • the intermediate thus obtained is then hydrogenated using a palladium on carbon catalyst or numerous other reagents such as platinum oxide or rhodium on aluminum oxide (see P.N. Rylander in Hydrogenation Methods , Academic Press, New York, 1985; Herbert O. House in Modern Synthetic Reactions , 2 nd ed., Chapter 1, pp. 1-45, 1972; and John Fried and John A. Edwards in Organic Reactions in Steroid Chemistry , Chapter 3, pp.
  • the intermediate is reacted with a reducing metal reagent, such as an alkali (group IA in the periodic table) or alkaline metal (group IIA in the periodic table), including Li, Na, or Ca, and an amine, such as NH 3 or ethylene diamine, in an aprotic solvent, such as THF or dioxane, at -78 °C to room temperature to give the compound of formula A-2.
  • a reducing metal reagent such as an alkali (group IA in the periodic table) or alkaline metal (group IIA in the periodic table)
  • an amine such as NH 3 or ethylene diamine
  • the compound of formula A-2 is reacted with (S)-(-)- ⁇ -methylbenzyiamine (as shown in Scheme A) and an electrophile such as methyl vinyl ketone (MVK), as shown in Scheme A.
  • MVK methyl vinyl ketone
  • the resulting major intermediate of formula A-3 may be ring closed or ring opened as illustrated in Scheme A.
  • the compound of formula A-2 is reacted with an electrophile such as MVK and a base such as sodium methoxide or potassium hydroxide or a racemic amine such as methylbenzylamine, piperidine, morphine or pyrrolidine in a solvent such as methanol to give a racemic mixture of the intermediates of formula A-3 and A-3a (as shown at the bottom of Scheme A).
  • a base such as sodium methoxide or potassium hydroxide
  • a racemic amine such as methylbenzylamine, piperidine, morphine or pyrrolidine
  • a solvent such as methanol
  • This reaction may also give directly a racemic mixture of the products A-4 and A-4a (as shown at the bottom of Scheme A), which mixtures may be resolved by chiral HPLC or by other literature methods for separating racemates.
  • the intermediate of formula A-3 is reacted with a base such as sodium methoxide or KOH in a solvent such as methanol or is reacted with an acid such as p-toluenesulfonic acid in a solvent such as toluene to give the compound of formula A-4, wherein R 2 is defined in the Summary above and wherein R x is halogen or methyl ether.
  • the compound of formula A-4 is prepared from the compound of formula A-3, by other reported annulation methods, some of which are described in M.E. Jung, Tetrahedron, 1976, 32, pp. 3-31.
  • the compound of formula A-4 wherein R x is, for example, methoxy is reacted with sodium ethanethiol in DMF or is reacted with methionine in methanesulfonic acid to give the compound of formula A-4 wherein R x is, for example, hydroxy.
  • the compound of formula A-4 wherein R x is, for example, hydroxy may be prepared by other literature methods as described in Protecting Groups in Organic Synthesis , Third Edition, T. W. Greene and P. G. M. Wuts, John Wiley and Sons, Inc. (1999) or as illustrated in Comprehesive Organic Transformation , R.C. Larock, VCH Publishers Inc. (1989), pp. 501-527.
  • the compound of formula A-4 wherein R 5 is methyl ether or hydroxy is reacted with a reducing metal reagent, such as an alkali (group IA in the periodic table) or alkaline metal (group IIA in the periodic table), including Li, Na, or Ca, and an amine such as NH 3 or ethylene diamine in an aprotic solvent such as THF or dioxane at -78 °C to room temperature to give the compounds of formula A-5 and A-5a wherein R 2 is defined in the Summary above and wherein the trans -compound of formula A-5 is the major product.
  • a reducing metal reagent such as an alkali (group IA in the periodic table) or alkaline metal (group IIA in the periodic table)
  • an amine such as NH 3 or ethylene diamine
  • an aprotic solvent such as THF or dioxane
  • the compound of formula A-4 from Scheme A wherein R x is halogen, methyl ether or hydroxy and R 2 is defined in the Summary above is treated with an alcohol or diol such as methanol, ethanol or ethylene glycol and a strong acid such as p-toluenesulfonic acid or HCI in an aprotic solvent such as toluene or benzene to form a ketal intermediate of formula B-1 wherein R a is lower alkyl or wherein the R a 's taken together with the two oxygen atoms form, for example, 1,3-dioxolane and wherein R 2 is defined in the Summary above.
  • this ketal intermediate may be prepared by other literature methods such as those described in Protecting Groups in Organic Synthesis , Third Edition, T. W. Greene and P. G. M. Wuts, John Wiley and Sons, Inc. (1999).
  • the ketal intermediate B-1 is hydrogenated using Pd(OH) 2 on carbon or other reagents, such as platinum oxide or rhodium on aluminum oxide (see P.N. Rylander in Hydrogenation Methods, Academic Press, New York, 1985; Herbert O. House in Modern Synthetic Reactions , 2 nd ed., Chapter 1, pp. 1-45, 1972; and John Fried and John A. Edwards in Organic Reactions in Steroid Chemistry , Chapter 3, pp. 111-145, 1972) in a solvent such as toluene from 15-2000 psi (which is about 1 to about 133 atm) H 2 at room temperature to 100°C.
  • Pd(OH) 2 on carbon or other reagents such as platinum oxide or rhodium on aluminum oxide (see P.N. Rylander in Hydrogenation Methods, Academic Press, New York, 1985; Herbert O. House in Modern Synthetic Reactions , 2 nd ed., Chapter 1, pp. 1-45, 1972; and John Fried and John A
  • this enol ether intermediate may be prepared by other literature methods such as those described in Protecting Groups in Organic Synthesis , Third Edition, T. W. Greene and P. G. M. Wuts, John Wiley and Sons, Inc. (1999).
  • the compound of formula B-3 wherein R x is, for example, bromide and the other variables are as defined above is reacted with a strong base such as n-butyl lithium, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, potassium bis(trimrthylsilyl)amide, potassium t-butoxide or others in an aprotic solvent, such as DMF or THF, and B(OiPr) 3 or other boron reagents known in the art, at -78°C to room temperature, depending on the nature of the base used.
  • the boron intermediate thus obtained is treated with a base, such as NaOH, and then a peroxide, such as hydrogen peroxide, to give the compound of formula B-3 wherein R x is, for example, hydroxy and the other variables are as defined above.
  • a strong base such as n-butyl lithium, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, potassium bis(trim
  • the enol ether intermediate of formula B-3 is then hydrogenated using Pd on CaCO 3 or K 2 CO 3 or other reagents such as platinum oxide or rhodium on aluminum oxide (see P.N. Rylander in Hydrogenation Methods , Academic Press, New York, 1985, Herbert O. House in Modern Synthetic Reactions , 2 nd ed., Chapter 1 pp. 1-45, 1972; and John Fried and John A. Edwards in "Organic Reactions in Steroid Chemistry," Chapter 3, pp. 111-145, 1972) in a variety of solvents including ethanol, methanol, THF or ethyl acetate at 15-60 psi (about 1-4 atm) H 2 pressure.
  • solvents including ethanol, methanol, THF or ethyl acetate at 15-60 psi (about 1-4 atm) H 2 pressure.
  • the resulting intermediate of formula B-4 is then reacted with an acid such as aqueous HCI, in a solvent such as ethanol, or THF or is reacted under other literature conditions, such as those described in Protecting Groups in Organic Synthesis , Third Edition, T. W. Greene and P. G. M. Wuts, John Wiley and Sons, Inc. (1999), to yield the compound of formula A-5 of Scheme A wherein R 5 is halogen, methyl ether or hydroxy and R 2 is defined in the Summary above.
  • the compound of formula A-5 is prepared from the compound of formula A-4 by other reported reduction methods, some of which are described in P. Jankowski, S. Marczak, J. Wicha, Tetrahedron, 1998, 12071-12150.
  • the compound of formula C-1 which is prepared as the compound of formula A-5 in Scheme A wherein R x is hydroxy, is reacted with trimethylsulfonium iodide ((CH 3 ) 3 S + I - ) and a base such as potassium t-butoxide in an aprotic solvent such as DMF to give the compound of formula C-2 wherein R 2 is defined in the Summary above.
  • the compound of formula C-2 is obtained from the compound of formula C-1 by other methods described in Comprehensive Organic Transformations , 2 nd ed., R.C. Larock, VCH Publishers Inc. (1999), pp. 944-947.
  • R 1 -Metal such as R 1 Li, R 1 MgBr or R 1 MgCl, wherein R 1 is, for example, alkynyl or alkyl, in an aprotic solvent such as THF at low temperature to give the desired isomer of formula C-3 wherein R 1 is alkynyl or alkyl and R 2 is defined in the Summary above.
  • the compound of formula C-1 is reacted with trimethylsilyltrifluoromethyl (TMSCF 3 ) and t-butylammoniumfluoride (TBAF) or cesium fluoride (CsF), as described in G.A. Olah et al., J . Am . Chem . Soc . (1989) 111 , 393, to give the compound of formula C-3 wherein R 1 is -CF 3 and R 2 is defined in the Summary above.
  • the compound of formula C-1 is treated with other -CF 3 nucleophiles which are known and available in the literature including, but not limited to, that disclosed by J. Russell, N. Roques, Tetrahedron, 1998, 54, 13771-13782.
  • R 1 -Metal such as R 1 Li, R 1 MgBr, or R 1 MgCl, wherein R 1 is, for example, alkyl
  • R 1 is, for example, alkyl
  • an aprotic solvent such as THF at low temperature
  • the compound of formula C-2 wherein R 2 is defined in the Summary above is reacted with lithium aluminum hydride or other hydride donors in an aprotic solvent such as THF, at room temperature to the refluxing temperature of the solvent used, to give the compound of the formula C-3 wherein R 1 is, for example, methyl, and R 2 is defined in the Summary above.
  • R 1 -O-Metal such as R 1 ONa, R 1 OK, R 1 OLi, wherein R 1 is, for example, alkyl
  • R 1 is, for example, alkyl
  • an aprotic solvent such as THF
  • the compound of formula C-3 wherein the variables are as defined above is reacted with a base such as NaH, t -butoxide or Et 3 N in an aprotic solvent such as DMF or CH 3 CN at a temperature which is between room temperature and 200°C depending on the nature of the solvent used, and is then reacted with an alkylating agent of formula NC-R b -V wherein R b is, for example, alkyl and V is a leaving group to give the compound of formula of C-4.
  • a base such as NaH, t -butoxide or Et 3 N
  • an aprotic solvent such as DMF or CH 3 CN
  • n is, for example, one to three is reacted with a hydroxyamine or its HCI salt in a protic solvent, such as ethanol or methanol, and a base such as K 2 CO 3 at a temperature between room temperature and 150 °C depending on the nature of the solvent used, to give the compound of formula C-5 wherein n is one to three, for example.
  • a protic solvent such as ethanol or methanol
  • a base such as K 2 CO 3
  • amidoxime of formula C-5 is then reacted with an acetylating agent such as carboxylic acid chloride, anhydride, or alkyl ester and a base such as pyridine in an aprotic solvent such as DMF to give the 1, 2, 4-oxadiazole compound of formula C-6.
  • an acetylating agent such as carboxylic acid chloride, anhydride, or alkyl ester and a base such as pyridine in an aprotic solvent such as DMF to give the 1, 2, 4-oxadiazole compound of formula C-6.
  • the 1, 2, 4-oxadiazole compound of formula C-6 can be obtained by reacting a compound of formula C-3 with a compound of formula Y, wherein X is a halogen or a leaving group such as tosylate or mesylate, n is, for example, one to three, and the other variables are as defined above, in the presence of a base and in an aprotic solvent.
  • the compounds of the present invention have improved physical and/or chemical properties, which would be beneficial in manufacturing and/or formulating these compounds.
  • Some of the preparation methods useful for the preparation of the compounds described herein may require protection of remote functionality (e.g., primary amine, secondary amine, carboxyl in Formula I precursors).
  • remote functionality e.g., primary amine, secondary amine, carboxyl in Formula I precursors.
  • the need for such protection will vary depending on the nature of the remote functionality and the conditions of the preparation methods.
  • the need for such protection and the use of such protection/deprotection is readily determined by one skilled in the art. For a general description of protecting groups and their use, see T.W. Greene, Protective Groups in Organic Synthesis , Third Edition, John Wiley & Sons, New York, 1999.
  • the subject invention also includes isotopically-labelled compounds, which are identical to those recited in Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 p, 32 p, 35 S, 18 F, and 36 Cl, respectively.
  • Compounds of the present invention, and pharmaceutically acceptable salts of said compounds, which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
  • Certain isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as 3 H or 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • Isotopically labelled compounds of Formula I of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes, Preparations and/or Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
  • any of the compounds and prodrugs of the present invention can be synthesized as pharmaceutically acceptable salts for incorporation into various pharmaceutical compositions.
  • pharmaceutically acceptable salts include hydrochloric, hydrobromic, hydroiodic, hydrofluoric, sulfuric, sulfonic, citric, camphoric, maleic, acetic, lactic, nicotinic, nitric, succinic, phosphoric, malonic, malic, salicyclic, phenylacetic, stearic, palmitic, pyridine, ammonium, piperazine, diethylamine, nicotinamide, formic, fumaric, urea, sodium, potassium, calcium, magnesium, zinc, lithium, cinnamic, methylamino, methanesulfonic, picric, p-toluenesulfonic, naphthalenesulfonic, tartaric, triethylamino, dimethylamino, and tris(hydroxymethyl)
  • Some of the compounds of the present invention are basic and they form a salt with a pharmaceutically acceptable anion. All such salts, including di-salts, are within the scope of the present invention and can be prepared by conventional methods. They can be prepared simply by contacting the basic entities, in either an aqueous, non-aqueous or partially aqueous medium.
  • the mesylate salt is prepared by reacting the free base form of the compound of Formula I with methanesulfonic acid under standard conditions.
  • the hydrochloride salt is prepared by reacting the free base form of the compound of Formula I with hydrochloric acid under standard conditions. The salts are recovered by filtration, by precipitation with a non-solvent followed by filtration, by evaporation of the solvent or, in the case of aqueous solutions, by lyophilization, as appropriate.
  • the compounds of the present invention and salts thereof may also include racemates, stereoisomers and mixtures of these compounds, including isotopically-labeled and radio-labeled compounds.
  • Such isomers can be isolated by standard resolution techniques, including fractional crystallization and chiral column chromatography.
  • the compounds of the present invention have asymmetric carbon atoms and are therefore enantiomers or diastereomers.
  • Diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical/chemical differences by methods known in the art, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diasteromeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomers, enantiomers and mixtures thereof are considered to be part of the present invention.
  • the compounds of the present invention can exist in several tautomeric forms, including the enol form, the keto form and mixtures thereof. All such tautomeric forms are included within the scope of the present invention.
  • the GR agonists, partial agonists and antagonists of the present invention modulate glucocorticoid receptor-mediated diseases.
  • these compounds can be used to influence the basic, life sustaining systems of the body, including carbohydrate, protein and lipid metabolism, electrolyte and water balance, and the functions of the cardiovascular, kidney, central nervous, immune, skeletal muscle and other organ and tissue systems.
  • GR modulators are used for the treatment of diseases associated with an excess or a deficiency of glucocorticoids in the body.
  • they may be used to treat the following: obesity, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), neurodegeneration (for example, Alzheimer's disease and Parkinson's disease), cognition enhancement, Cushing's Syndrome, Addison's Disease, osteoporosis, frailty, inflammatory diseases (such as osteoarthritis, rheumatoid arthritis, asthma and rhinitis), tests of adrenal function, viral infection, immunodeficiency, immunomodulation, autoimmune diseases, allergies, wound healing, compulsive behavior, multi-drug resistance, addiction, psychosis, anorexia, cachexia, post-traumatic stress syndrome, post-surgical bone fracture, medical catabolism and prevention of muscle frailty.
  • HAV human immunodeficiency virus
  • AIDS acquired immunodeficiency syndrome
  • neurodegeneration for example, Alzheimer's disease and Parkinson's disease
  • cognition enhancement for example,
  • the present invention relates to compounds useful for treating disorders such as the following: endocrine disorders (such as primary or secondary adrenocortical insufficiency; congenital adrenal hyperplasia, nonsuppurative thyroiditis and hypercalcemia associated with cancer); arthritis (such as osteoarthritis; psoriatic arthritis; rheumatoid arthritis; juvenile rheumatoid arthritis; ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; post-traumatic osteoarthritis; synovitis of osteoarthritis and epicondylitis); collagen diseases (such as exacerbation or as maintenance therapy in systemic lupus erythematosus, acute rheumatic carditis and systemic dermatomyositis (polymyositis)); dermatologic diseases (such as pemphigus, bullous dermatitis herpetiformis, erythema
  • the compounds of the present invention, and pharmaceutically acceptable salts thereof are useful to induce weight loss in mammals needing or desiring to lose weight. While not intending to limit the present invention to a specific mechanism of action, the compounds of the present invention, and prodrugs and salts thereof, are able to induce weight loss by a variety of mechanisms, such as appetite suppression, decreasing food intake and stimulation of the metabolic rate in peripheral tissue, thereby increasing energy expenditure. In addition, the compounds of the present invention and salts thereof are useful to induce a more favorable partitioning of nutrients from fat to muscle tissue in mammals. Thus, while not necessarily resulting in weight loss, this increase in muscle mass may be useful in preventing or treating diseases, such as obesity and frailty.
  • the compounds of the present invention and pharmaceutically acceptable salts thereof may also be useful to increase lean meat deposition, improve lean meat to fat ratio, and trim unwanted fat from non-human animals, as described further below.
  • compositions and compounds of the present invention and pharmaceutically acceptable salts thereof will generally be administered daily in the form of a dosage unit (e.g., tablet, capsule, etc.) at a therapeutically effective amount of such compound, prodrug or salt thereof from about 0.1 ⁇ g/kg of body weight to about 500 mg/kg of body weight, more particularly from about 1 ⁇ g/kg to about 250 mg/kg, and most particularly from about 2 ⁇ g/kg to about 100 mg/kg. More preferably, a compound of the present invention will be administered at an amount of about 0.1 mg/kg to about 500 mg/kg of body weight, and most preferably from about 0.1 mg/kg to about 50 mg/kg of body weight.
  • the particular quantity of pharmaceutical composition according to the present invention administered to a patient will depend upon a number of factors, including, without limitation, the activity desired, the condition of the patient, and tolerance for the compound.
  • the compounds and pharmaceutically acceptable salts thereof can be used in a wide variety of combination therapies to treat the conditions and diseases described above.
  • the compounds and pharmaceutically acceptable salts thereof of the present invention can be used in conjunction with (e.g., simultaneously or sequentially) other pharmaceutical agents for the treatment of the disease/conditions described herein.
  • they may be used in combination with pharmaceutical agents that treat obesity, diabetes, inflammatory disease, immunodefficiency, hypertension, cardiovascular disease, viral infection, HIV, Alzheimers's disease, Parkinson's disease, anxiety, depression, or psychosis.
  • both the compounds, and pharmaceutically acceptable salts thereof of this invention and the other drug therapies are administered to mammals (e.g., humans, male or female) by conventional methods.
  • glucocorticoid receptor agonists are efficacious agents for the treatment of various inflammatory diseases; however, treatment is often accompanied by undesirable side effects. These side effects include, but are not limited to, the following examples: metabolic effects, weight gain, muscle wasting, decalcification of the skeleton, osteoporosis, thinning of the skin and thinning of the skeleton.
  • glucocorticoid receptor modulators may be used in combination with glucocorticoid receptor agonists to block some of these side effects, without inhibiting the efficacy of the treatment.
  • any glucocorticoid receptor agonist may be used as the second compound in the combination aspect of the present invention.
  • glucocorticoid receptor modulators include those known in the art (many of which are described above) as well as the compounds of the present invention. More particularly, examples of glucocorticoid receptor modulators known in the art include, but are not limited to, certain nonsteroidal compounds, such as 5H-chromeno[3,4-f]quinolines, which are selective modulators of steroid receptors, as disclosed in U.S. Patent No.
  • glucocorticoid receptor agonists include those known in the art, such as prednisone (17,21-dihydroxypregnane-1,4-diene-3,11,20-trione), prednylidene ((11 ⁇ )-11,17,21-trihydroxy-16-methylenepregna-1,4-diene-3, 20-dione), prednisolone ((11 ⁇ )-11,17,21-trihydroxypregna-1,4-diene-3, 20-dione), cortisone (17 ⁇ ,21-dihydroxy-4-pregnene-3,11,20-trione), dexamethasone ((11 ⁇ , 16 ⁇ )-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-
  • prednisone or an equivalent compound may be administered from about 5 to about 80 mg, depending on the condition; hydrocortisone may be administered from about 100 to about 400 mg, depending on the condition; and dexamethasone may be administered from about 4 to about 16 mg, depending on the condition.
  • doses are typically administered once to twice daily, and for maintenance purposes, sometimes on alternate days.
  • any cholinomimetic drug such as donepezil hydrochloride (ARICEPT®)
  • ARICEPT® donepezil hydrochloride
  • any anti-Parkinson's drug such as L-dopa, bromocriptine, or selegiline, may be used as the second compound in the combination aspect of this invention.
  • any antianxiolytic drug such as benzodiazepine, valium, or librium, may be used as the second compound in the combination aspect of this invention.
  • any tricyclic antidepressant such as, desipramine, or any selective serotonin reuptake inhibitor (SSRI's), such as sertraline hydrochloride or fluoxetine hydrochloride, may be used as the second compound in the combination aspect of this invention.
  • SSRI's selective serotonin reuptake inhibitor
  • any typical or atypical antipsychotic drug such as haloperidol or clozapine may be used as the second compound in the combination aspect of this invention.
  • aldose reductase inhibitor refers to a compound which inhibits the bioconversion of glucose to sorbitol catalyzed by the enzyme aldose reductase. Such inhibition is readily determined by those skilled in the art according to standard assays (J. Malone, Diabetes, 29:861-864, 1980, "Red Cell Sorbitol, an Indicator of Diabetic Control").
  • aldose reductase inhibitors are described and referenced below; however other aldose reductase inhibitors will be known to those skilled in the art.
  • Examples of aldose reductase inhibitors include compounds such as those disclosed and described in WO 99/43663, published 2 September 1999.
  • glycogen phosphorylase inhibitor refers to any substance or agent or any combination of substances and/or agents which reduces, retards or eliminates the enzymatic action of glycogen phosphorylase.
  • the currently known enzymatic action of glycogen phosphorylase is the degradation of glycogen by catalysis of the reversible reaction of a glycogen macromolecule and inorganic phosphate to glucose-1-phosphate and a glycogen macromolecule which is one glucosyl residue shorter than the original glycogen macromolecule (forward direction of glycogenolysis).
  • sorbitol dehydrogenase inhibitor refers to a compound which inhibits the enzyme sorbitol dehydrogenase, which catalyzes the oxidation of sorbitol to fructose. Such inhibition is readily determined by those skilled in the art according to standard assays (as described in U.S. Patent No. 5,728,704 and references cited therein). A variety of these compounds are described and referenced below; however other sorbitol dehydrogenase inhibitors will be known to those skilled in the art.
  • 5,728,704 discloses substituted pyrimidines which inhibit sorbitol dehydrogenase, lower fructose levels, and/or treat or prevent diabetic complications, such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic microangiopathy and diabetic macroangiopathy.
  • any known, commercially marketed antidiabetic compound may be used as the second compound in the combination aspect of this invention.
  • a variety of such compounds are described and referenced below; however other such compounds will be known to those skilled in the art.
  • Examples of such compounds useful in the compositions and methods of this invention include, for example, insulin, inhaled insulin, metformin, and sulfonylureas, such as glipazide (GLUCOTROL®), glyburide (GLYNASE®, MICRONASE®) and chlorpropamide (DIABINASE®).
  • ⁇ -Adrenergic agents have been categorized into ⁇ 1 , ⁇ 2 , and ⁇ 3 subtypes. Agonists of ⁇ -receptors promote the activation of adenyl cyclase. Activation of ⁇ 1 receptors invokes increases in heart rate. Activation of ⁇ 2 receptors induces relaxation of smooth muscle tissue which produces a drop in blood pressure and the onset of skeletal muscle tremors. Activation of ⁇ 3 receptors is known to stimulate lipolysis, which is the breakdown of adipose tissue triglycerides to glycerol and fatty acids.
  • ⁇ 3 receptors Activation of ⁇ 3 receptors also stimulates the metabolic rate, thereby increasing energy expenditure. Accordingly, activation of ⁇ 3 receptors promotes the loss of fat mass. Compounds that stimulate ⁇ 3 receptors are therefore useful as anti-obesity agents. Compounds which are ⁇ 3 -receptors agonists have hypoglycemic and/or anti-diabetic activity. Such activity is readily determined by those skilled in the art according to standard assays (International Patent Application, Publication No. WO 96/35671). Several compounds are described and referenced below; however, other ⁇ -adrenergic agonists will be known to those skilled in the art. International Patent Application, Publication No.
  • WO 96/35671 discloses compounds, such as substituted aminopyridines, which are ⁇ -adrenergic agonists.
  • International Patent Application, Publication No. 93/16189 discloses the use of selective ⁇ 3 receptor agonists in combination with compounds which modify eating behavior for the treatment of obesity.
  • Any thyromimetic antiobesity agent may be used as the second compound in the combination aspect of this invention.
  • These compounds are tissue selective thyroid hormone agonists. These compounds are able to induce weight loss by mechanisms other than appetite suppression, e.g., through stimulation of the metabolic rate in peripheral tissue, which, in turn, produces weight loss.
  • Such metabolic effect is readily measured by those skilled in the art according to standard assays. A variety of these compounds will be known to those skilled in the art. It is well known to one of ordinary skill in the art that selectivity of the thermogenic effect is an important requirement for a useful therapeutic agent in the treatment of, for example, obesity and related conditions.
  • Any eating behavior modifying compound may be used as the second compound of this invention.
  • Compounds which modify eating behavior include anorectic agents, which are compounds that diminish the appetite.
  • anorectic agents are well known to one of ordinary skill in the art.
  • a variety of these compounds which are anorectic agents will be known to those skilled in the art.
  • antiobesity agents phenylpropanolamine, ephedrine, pseudoephedrine, phentermine, a Neuropeptide Y (hereinafter also referred to as "NPY") antagonist, a cholecystokinin-A (hereinafter referred to as CCK-A) agonist, a monoamine reuptake inhibitor (such as sibutramine), a sympathomimetic agent, a serotoninergic agent (such as fenfluramine or fenfluramine), a dopamine agonist (such as bromocriptine), a melanocyte-stimulating hormone receptor agonist or mimetic, a melanocyte-stimulating hormone analog, a cannabinoid receptor antagonist, a melanin concentrating hormone antagonist, the OB protein (hereinafter referred to as "leptin”), a leptin analog, a galanin antagonist or a Gl lipase inhibitor or decreaser (leptin”),
  • antiobesity agents include phosphatase 1B inhibitors, bombesin agonists, dehydroepiandrosterone or analogs thereof, glucocorticoid receptor antagonists, orexin receptor antagonists, urocortin binding protein antagonists or glucagon-like peptide-1 (insulinotropin) agonists.
  • a particularly preferred monoamine reuptake inhibitor is sibutramine, which can be prepared as disclosed in U.S. Patent No. 4,929,629.
  • Preferred serotoninergic agents include fenfluramine and fenfluramine, which can be prepared as disclosed in U.S. Patent No. 3,198,834.
  • a particularly preferred dopamine agonist is bromocriptine, which can be prepared as disclosed in U.S. Patent Nos. 3,752,814 and 3,752,888.
  • Another preferred anorectic agent is phentermine, which can be prepared as disclosed in U.S. Patent No. 2,408,345.
  • NPY receptors antagonist refers to compounds which interact with NPY receptors and inhibit the activity of neuropeptide Y at those receptors and thus are useful in treating disorders associated with neuropeptide Y, such as feeding disorders, including obesity. Such inhibition is readily determined by those skilled in the art according to standard assays (such as those described in International Patent Application, Publication No. WO 99/07703).
  • the compounds described and referenced below are NPY receptors antagonists; however, other NPY receptors antagonists will also be known to those skilled in the art.
  • WO 99/07703 discloses certain 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide Y receptor antagonists.
  • both the compounds of this invention and the other compound therapies are administered to mammals (e.g., humans, male or female) by conventional methods.
  • mammals e.g., humans, male or female
  • the therapeutically effective amounts of the compounds of this invention and the other compound therapies to be administered to a patient in combination therapy treatment will depend upon a number of factors, including, without limitation, the biological activity desired, the condition of the patient, and tolerance for the compound.
  • the second compound of this invention when administered to a mammal, is dosed at a range between about 0.01 to about 50 mg/kg/day body weight, preferably about 0.1 mg/kg/day to about 10 mg/kg/day body weight, administered singly or as a divided dose.
  • the dosage of sibutramine is about 0.01 mg/kg/day to about 30 mg/kg/day body weight, preferably about 0.1 mg/kg/day to about 1 mg/kg/day body weight;
  • fenfluramine the dosage of fenfluramine is about 0.01 mg/kg/day to about 30 mg/kg/day body weight, preferably about 0.1 mg/kg/day to about 1 mg/kg/day body weight;
  • bromocriptine the dosage of bromocriptine is about 0.01 to about 10 mg/kg/day body weight, preferably 0.1 mg/kg/day to about 10 mg/kg/day body weight;
  • phentermine the dosage of phentermine is about 0.01 mg/kg/day to about 10 mg/kg/day, preferably about 0.1 mg/kg/day to about 1 mg/kg/day body weight.
  • an amount of an aldose reductase inhibitor that is effective for the activities of this invention may be used as the second compound of this invention.
  • an effective dosage for aldose reductase inhibitors for this invention is in the range of about 0.1 mg/kg/day to about 100 mg/kg/day in single or divided doses, preferably about 0.1 mg/kg/day to about 20 mg/kg/day in single or divided doses.
  • the compounds and pharmaceutically acceptable salts of the present invention can be combined in a mixture with a pharmaceutically acceptable carrier, vehicle or diluent to provide pharmaceutical compositions useful for treating the conditions or disorders noted herein in mammalian, and more preferably, in human, patients.
  • a pharmaceutically acceptable carrier, vehicle or diluent employed in these pharmaceutical compositions may take a wide variety of forms depending upon the type of administration desired, for example, intravenous, oral, topical, suppository or parenteral.
  • the compounds, prodrugs and salts thereof of this invention can be administered individually or together in any conventional dosage form, such as an oral, parenteral, aerosol, rectal or transdermal dosage form.
  • a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules and powders.
  • Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
  • compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the compounds and pharmaceutically acceptable salts thereof of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.
  • tablets and capsules represent the most advantageous oral dosage form for the pharmaceutical compositions of the present invention.
  • solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts.
  • aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes.
  • the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.
  • aqueous or partially aqueous solutions are prepared.
  • the compounds, prodrugs and pharmaceutically acceptable salts thereof of the present invention may be formulated using bland, moisturizing bases, such as ointments or creams.
  • suitable ointment bases are petrolatum, petrolatum plus volatile silicones, lanolin, and water in oil emulsions.
  • kits comprises two separate pharmaceutical compositions: a compound of formula I or a salt of such compound, and a second compound as described above.
  • the kit comprises a container, such as a divided bottle or a divided foil packet.
  • the kit comprises directions for the administration of the separate components.
  • the kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
  • Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets or capsules). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be packed. Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet.
  • the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
  • a memory aid on the kit, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested.
  • a memory aid is a calendar printed on the card, e.g., as follows "First Week, Monday, Tuesday, ...etc.... Second Week, Monday, Tuesday, etc.
  • a “daily dose” can be a single tablet or capsule or several pills or capsules to be taken on a given day.
  • a daily dose of formula I compound (or pharmaceutically acceptable salt thereof) can consist of one tablet or capsule while a daily dose of the second compound can consist of several tablets or capsules and vice versa.
  • the memory aid should reflect this.
  • a dispenser designed to dispense the daily doses one at a time in the order of their intended use.
  • the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen.
  • a memory-aid is a mechanical counter which indicates the number of daily doses that has been dispensed.
  • a battery-powered microchip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
  • a therapeutically effective dose is received, generally a daily dose which, when administered orally to an animal, is usually between 0.01 and 500 mg/kg of body weight, preferably between 0.1 and 50 mg/kg of body weight.
  • the medication can be carried in the drinking water so that a therapeutic dosage of the agent is ingested with the daily water supply.
  • the agent can be directly metered into drinking water, preferably in the form of a liquid, water-soluble concentrate (such as an aqueous solution of a water soluble salt).
  • the active ingredient can also be added directly to the feed, as such, or in the form of an animal feed supplement, also referred to as a premix or concentrate.
  • a premix or concentrate of therapeutic agent in a carrier is more commonly employed for the inclusion of the agent in the feed.
  • Suitable carriers are liquid or solid, as desired, such as water, various meals such as alfalfa meal, soybean meal, cottonseed oil meal, linseed oil meal, corncob meal and corn meal, molasses, urea, bone meal, and mineral mixes such as are commonly employed in poultry feeds.
  • a particularly effective carrier is the respective animal feed itself; that is, a small portion of such feed.
  • the carrier facilitates uniform distribution of the active materials in the finished feed with which the premix is blended. It is important that the compound be thoroughly blended into the premix and, subsequently, the feed.
  • the agent may be dispersed or dissolved in a suitable oily vehicle such as soybean oil, corn oil, cottonseed oil or in a volatile organic solvent and then blended with the carrier. It will be appreciated that the proportions of agents in the concentrate are capable of wide variation since the amount of agent in the finished feed may be adjusted by blending the appropriate proportion of premix with the feed to obtain a desired level of therapeutic agent.
  • High potency concentrates may be blended by the feed manufacturer with a proteinaceous carrier such as soybean oil meal and other meals, as described above, to produce concentrated supplements which are suitable for direct feeding to animals. In such instances, the animals are permitted to consume the usual diet. Alternatively, such concentrated supplements may be added directly to the feed to produce a nutritionally balanced, finished feed containing a therapeutically effective level of a compound according to the present invention.
  • the mixtures are thoroughly blended by standard procedures, such as in a twin shell blender, to ensure homogeneity.
  • the supplement is used as a top dressing for the feed, it likewise helps to ensure uniformity of distribution of the active material across the top of the dressed feed.
  • the present invention has several advantageous veterinary features.
  • the present invention provides the means by which this can be accomplished.
  • using the method of the present invention yields leaner animals which command higher prices from the meat industry.
  • Drinking water and feed effective for increasing lean meat deposition and for improving lean meat to fat ratio are generally prepared by mixing a compound of the present invention with a sufficient amount of animal feed to provide from about 10 -3 to 500 ppm of the compound in the feed or water.
  • the preferred medicated swine, cattle, sheep and goat feed generally contain from about 1 to 400 grams of active ingredient per ton of feed, the optimum amount for these animals usually being about 50 to 300 grams per ton of feed.
  • the preferred feed of domestic pets usually contain about 1 to 400 grams and preferably about 10 to 400 grams of compound per ton of feed.
  • the compounds and pharmaceutically acceptable salts of the present invention may be prepared in the form of a paste or a pellet and administered as an implant, usually under the skin of the head or ear of the animal in which increase in lean meat deposition and improvement in lean mean to fat ratio is sought.
  • parenteral administration involves injection of a sufficient amount of a compound and pharmaceutically acceptable salt of the present invention to provide the animal with 0.01 to 500 mg/kg/day of body weight of the compound.
  • the preferred dosage for poultry, swine, cattle, sheep, goats and domestic pets is in the range of from 0.1 to 50 mg/kg/day of body weight of compound.
  • Paste formulations can be prepared by dispersing a compound of this invention in a pharmaceutically acceptable oil such as peanut oil, sesame oil or corn oil.
  • Pellets containing an effective amount of a compound, prodrug and pharmaceutically acceptable salt of the present invention can be prepared by admixing a compound of the present invention with a diluent such as carbowax, and carnuba wax, and a lubricant, such as magnesium or calcium stearate, can be added to improve the pelleting process.
  • a diluent such as carbowax, and carnuba wax
  • a lubricant such as magnesium or calcium stearate
  • HeLa cells containing endogenous human glucocorticoid receptors are transfected with a 3xGRE-luciferase plasmid generated by standard procedures and a plasmid conferring neomycin resistance.
  • Novel glucocorticoid responsive cell lines are generated and characterized.
  • One such cell line designated HeLa-GRE9 is used for determining the activity of compounds at the glucocorticoid receptor.
  • Cells are maintained in charcoal-stripped serum and transferred to 96-well microtiter plates one day prior to treatment with various concentrations (10 -12 to 10 -5 ) of test compounds in the absence and presence of known glucocorticoid receptor agonists (i.e., dexamethasone, hydrocortisone) for up to 24 hours. Treatments are performed in triplicate. Cell lysates are prepared and luciferase activity is determined using a luminometer. Agonist activity is assessed by comparing the luciferase activity from cells treated with test compound to cells treated with the agonist, dexamethasone.
  • glucocorticoid receptor agonists i.e., dexamethasone, hydrocortisone
  • Antagonist activity is assessed by comparing the luciferase activity of an EC 50 concentration of dexamethasone in the absence and presence of test compound.
  • the EC 50 concentration that produced 50% of the maximal response
  • the EC 50 is calculated from dose response curves.
  • Binding protocol Compounds are tested in a binding displacement assay using human glucocorticoid receptor expressed in Sf9 cells with 3 H-dexamethasone as the ligand. Human glucorticoid receptor is expressed in Sf9 cells as described in Mol. Endocrinology 4: 209, 1990. Pellets containing Sf9 cells expressing the human GR receptor from 1L vats are lysed with 40 ul of 20mM AEBSF stock (Calbiochem, LaJolla, CA) containing 50 mg/ml leupeptin and 40 ml of homogenization buffer is added.
  • 20mM AEBSF stock Calbiochem, LaJolla, CA
  • the assay is carried out in 96-well polypropylene plates in a final volume of 130 ul containing 200 ug Sf9 lysate protein, 6.9 nM 3 H-dexamethasone (Amersham, Arlington Heights, IL) in presence of test compounds, test compound vehicle (for total counts) or excess dexamethasone (7 uM nonradioactive, to determine non-specific binding) in an appropriate volume of assay buffer. All compounds are tested at 6 concentrations in duplicate (concentration range 0.1-30 nM or 3-1000 nM). Test compounds are diluted from a 25 mM stock in 100% DMSO with 70%EtOH and added in a volume of 2 ⁇ l. Once all additions are made the plates are shaken, sealed with sealing tape and incubated at 4 °C overnight.
  • dextran coated charcoal Assay buffer 75 ⁇ l of dextran coated charcoal (5.0 g activated charcoal, 0.5 g dextran adjusted to volume of 100 ml with assay buffer) is added, plates are shaken and incubated for five minutes at 4 °C. Plates are then centrifuged in a refrigerated benchtop centrifuge at top speed for 15 minutes. One hundred ⁇ l of the supernatant from each well is placed into a 96-well PET plate with 200 ⁇ l of scintillation cocktail and counted on a beta counter (1450 MicroBetaTrilux, from Wallac, Turku, Finland).
  • Assay Buffer 2.0 ml 1M Tris, 0.2 ml 0.5mM EDTA, 77.1 mg DTT, 0.243 g sodium molybdate in a volume of 100 ml water; Homogenization buffer: 2.0 ml 0.5 M K 2 HPO 4 (pH 7.6), 20 ⁇ l 0.5 M EDTA (pH 8.0), 77.1 mg DTT, 0.486 g sodium molybdate in a volume of 100 ml water.
  • T47D cells from ATCC containing endogenous human progesterone and mineralocorticoid receptors are transiently transfected with a 3xGRE-luciferase using Lipofectamine Plus (GIBCO-DRL, Gaithersburg, MD). Twenty-four hours post-transfection cells are maintained in charcoal-stripped serum and transferred to 96-well microtiter plates. The next day cells are treated with various concentrations (10 -12 to 10 -5 ) of test compounds in the absence and presence of a known progesterone receptor agonist (progesterone) and a known mineralocorticoid receptor agonist (aldosterone) for up to 24 hours.
  • progesterone progesterone
  • aldosterone mineralocorticoid receptor agonist
  • Treatments are performed in triplicate.
  • Cell lysates are prepared and luciferase activity is determined using a luminometer.
  • Agonist activity is assessed by comparing the luciferase activity from cells treated with compound alone to cells treated with either the agonist progesterone or aldosterone.
  • Antagonist activity is assessed by comparing the luciferase activity of an EC 50 concentration of progesterone or aldosterone in the absence and presence of compound.
  • the EC 50 concentration that produced 50% of maximal response for progesterone and aldosterone is calculated from dose response curves.
  • the obese, diabetic ob/ob mouse is used to assess the anti-diabetes and anti-obesity activity of the compounds.
  • Six to 10 week old ob/ob male mice (Jackson Labs, Bar Harbor, Maine) are dosed with test compound for 2 to 10 days.
  • Plasma glucose levels are determined by measuring glucose from samples obtained by orbital bleeding.
  • Glucose is quantitated using an Abbott Autoanalyzer (Abbott, Inc., Abbott Park, IL). Food intake is monitored on a daily basis by differential weighing.
  • TAT liver tyrosine amino transferase
  • mice Male Sprague Dawley rats (from Charles River, Wilimington MA) (adrenal-intact or adrenalectomized at least one week prior to the screen) b.w. 90g are used. The rats are housed under standard conditions for 7-10d prior to use in the screen.
  • Rats (usually 3 per treatment group) are dosed with test compound, vehicle or positive control (Ru486) either i.p., p.o., s.c. or i.v. (tail vein).
  • the dosing vehicle for the test compounds is typically one of the following: 100% PEG 400, 0.25% methyl cellulose in water, 70% ethanol or 0.1 N HCI and the compounds are tested at doses ranging from 10 to 125 mg/kg.
  • the compounds are dosed in a volume of 1.0 ml/ 100 g body weight (for p.o.) or 0.1 ml/100g body weight for other routes of administration .
  • the rats are injected with dexamethasone (0.03 mg/kg i.p. in a volume of 0.1 ml/ 100g) or vehicle.
  • dexamethasone from Sigma, St. Louis, MO
  • water final: 10% ethanol:90% water, vol:vol.
  • Groups treated with vehicle-vehicle, vehicle-dexamethasone, and Ru486-dexamethasone are included in each screen.
  • the compounds are tested vs. dexamethasone only. Three hours after the injection of dexamethasone the rats are sacrificed by decapitation.
  • liver homogenate is excised and placed in 2.7 ml of ice cold buffer and homogenized with a polytron. To obtain cytosol the liver homogenate is centrifuged at 105,000g for 60 min and the supernatant is stored at -80 °C until analysis. TAT is assayed on 100 ul of a 1:20 dilution of the 105,000g supernatant using the method of Granner and Tomkins (Methods in Enzymology 17A: 633-637, 1970) and a reaction time of 8-10 minutes. TAT activity is expressed as umol product/min/g liver.
  • Treatment data are analyzed by using analysis of variance (ANOVA) with protected least significant difference (PLSD) post-hoc analysis.
  • ANOVA analysis of variance
  • PLSD protected least significant difference
  • This assay the glucocorticoid inhibition of IL-1 (Interleukin-1) induced MMP-1 (Matrix Metalloproteinase-1) and IL-8 (Interleukin-8) production in human chondrosarcoma cells, is conducted as follows: SW1353 human chondrosarcoma cells (obtained from ATCC) from passage 12 through passage 19 are used in a 96 well format assay.
  • DMEM Dulbecco's Modified Eagle Medium
  • serum containing media is removed and replaced with 200 ul/well DMEM containing 1 mg/L insulin, 2 g/L lactalbumin hydrosylate, and 0.5 mg/L ascorbic acid and returned to incubation at 37 °C, 5% CO 2 .
  • serum free media is removed and replaced with 150 ul/well fresh serum free media containing +/- 20 ng/ml IL-1 beta, +/- 5 nM dexamethasone, +/- compound.
  • the percent of the average IL-1 control is determined for the average of each of the triplicate samples following subtraction of the average signal from untreated cells. IC 50 's are determined from log linear plots of the percent of control versus the concentration of inhibitor. At 72 hours after IL-1 addition, the remaining media is removed and stored at -20 °C until time of MMP-1 production analysis. MMP-1 production is assessed via the Bio-Trak MMP-1 ELISA kit from Amersham (RPN2610) on 100 ul of neat sample following the manufacturer's protocol.
  • the percent of the average IL-1 control is determined for the average of each of the triplicate samples following subtraction of the average signal from untreated cells.
  • IC 50 's are determined from log linear plots of the percent of control versus the concentration of inhibitor.
  • the reaction solution was cooled to 0° C and 17 mL of acetic acid and 14 mL of H 2 O were added and the resultant solution was allowed to warm to RT for 2 h.
  • the solution was poured into H 2 O and extracted three times with EtOAc.
  • the combined organic layers were washed with 1 N HCI, H 2 O, saturated NaHCO 3 , then dried over Na 2 SO 4 , filtered, and evaporated to dryness.
  • the crude product was purified by chromatography over SiO 2 using 15% EtOAc to 35% EtOAc in hexanes as the gradient eluant to give 48 g of the title product of this preparation as a yellow solid.
  • the title product of this preparation can be obtained by the following method: A solution of 9.45 g (0.02971 mol) of the title product of Preparation 3 and 6.65 g (0.04458 mol) of DL-methionine in 200 ml of methane sulfonic acid under nitrogen was stirred at room temperature. The resultant solution was allowed to stir overnight. Ice water was then poured into the mixture, and the precipitate was filtered. The filter cake was washed with water and taken into ethyl acetate. The organic layer was washed with NaHCO 3 (sat), dried over Na 2 SO 4 and concentrated to give 8 g of the title product of this preparation as an off-white powder (90%).
  • the reaction was heated to 150 °C under Dean-Stark conditions. After 2 hr, about 13 mL of water was collected and concentration of a small sample showed the reaction was complete by NMR.
  • the toluene solution of pyrrolidine enamine was cooled to 90 °C and benzyl bromide (105 mL, 912 mmol) was added dropwise. After 30 min, solids began to granulate and the solution became very thick. An additional 500 mL of toluene was added to aid stirring and heating was continued at 90 °C for 2 h. The slurry was allowed to cool to room temperature and granulate overnight. The solids were filtered and washed with toluene (2 x 500 mL).
  • the reaction mixture was added slowly to the acetyl chloride solution such that the temperature remained at about 0 °C. Once addition was complete the resulting solids were allowed to granulate for 1 h at 0 °C. The solids were filtered and washed with 2B ethanol (2 x 100 mL) and placed in a vacuum oven at room temperature overnight. The resulting solids contained 7.59% NaCI ash and could be taken on without purification.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Claims (13)

  1. Un composé de Formule I
    Figure 00750001
       ou un sel pharmaceutiquement acceptable dudit composé ;
    dans lequel R1 représente un groupe a) -alkyle C1-C6 facultativement substitué par -CF3, b) -C≡C-CH3, c) -C≡C-CI, d) -C≡C-CF3, e) -CH2O-alkyle C1-C4 facultativement substitué par -CF3 ou f) -CF3 ;
       R2 représente un groupe a) -alkyle C1-C5, b) -alcényle C2-C5 ou c) -phényle facultativement substitué par un des groupes suivants : -OH, -NR8R9, -NR8-C(O)-alkyle Ci-C4, -CN, -Z-hét, -O-alkyle C1-C3-C(O)-NR8R9, -NR8-Z-C(O)-NR8R9, -Z-NR8-SO2-R9, -NR8-SO2-hét, -O-C(O)-alkyle C1-C4 ou -O-SO2-alkyle C1-C4 ;
       Z, chaque fois qu'il apparaít, est indépendamment un -alkyle Co-C4 ;
       R3 représente un groupe a) -alkyle C1-C6, b) -Z-NR4R5 ou c) -Z-hét ;
       R4 et R5 représentent, indépendamment l'un de l'autre un a) hydrogène ou b) l -alkyle C1-C3 ;
       hét est un cycle hétérocyclique à 5, 6 ou 7 membres saturé, partiellement saturé ou insaturé, facultativement substitué, contenant 1 à 3 hétéroatomes choisis dans le groupe composé de l'azote, l'oxygène et du soufre et comprenant un groupe bicyclique quelconque dans lequel un quelconque des cycles hétérocycliques ci-dessus est fusionné à un noyau benzène ou à un autre cycle hétérocyclique, et facultativement substitué par un à trois groupes R6 ;
       R6 représente un groupe a) -alkyle C1-C6 facultativement substitué par un à trois groupes R7, b) -Z-NR8R9 ou c) -Z-C(O)-NR8R9 ;
       R7 , chaque fois qu'il apparaít, est indépendamment un a) halo, b) -OH, c) oxo ou d) - O-alkyle C1-C6 ;
       R8 et R9, chaque fois qu'ils apparaissent, sont indépendamment un a) -H ou b) alkyle C1-C3;
       ou R8 et R9 sont combinés à N pour former hét;
       n est égal à un, deux ou trois ;
       sous réserve que :
    1) lorsque R1 est -C≡C-CH3, R2 est un phényle et n est égal à un, alors R3 est autre que - CH2N(CH3)2, -(CH2)2-N(CH3)2. -CH2-pipéridinyle ou -(CH2)2-morpholinyle ;
    2) lorsque R1 est (CH2)2-CH3, R2 est un phényle et n est égal à un, alors R3 est autre que t-butyle ou -3,5-diméthyl-4-isoxazolyle.
  2. Un composé selon la revendication 1 de Formule II
    Figure 00760001
    ou un sel pharmaceutiquement acceptable dudit composé ;
    dans lequel R1 est un groupe a) -alkyle C1-C6 facultativement substitué par CF3, b) C≡C-CH3, c) CF3 ou d) CH2O-alkyle C2-C4 ; n est égal à un ou deux.
  3. Un composé selon la revendication 2
    dans lequel R3 représente -alkyle C1-C2-NR4R5 ;
       R4 et R5 sont, indépendamment l'un de l'autre, un a) méthyle, b) éthyle, c) propyle ou d) isopropyle.
  4. Un composé selon la revendication 2
    dans lequel R3 est -alkyle C0-C2-hét ;
       hét est un a) morpholinyle, b) pyrrolidinyle, c) pipéridinyle, d) pipérazinyle, e) hexahydro-azépinyle, f) azabicyclo[2.2.2]oct-3-yle, g) azabicyclot[3.2.1]oct-3-yle, h) 3,6-diazabicyclo[3.1.1]heptyle, i) 2,5-diazabicyclo[2.2.1]heptyle, j) 1,2,5,6-tétrahydro-pyridinyle, k) azétidinyle, l) 1,4-diazabicyclo[3.2.2]nonanyle, m) 3,6-diazabicyclo[3.2.2]nonanyle, n) octahydro-pyrido[1,2-a]pyrazinyle ou o) hexahydro-1,4-diazépinyle ;
       les groupes hét ci-dessus sont facultativement substitués par un ou deux groupes R6 ;
       R6, chaque fois qu'il apparaít, est indépendamment a) méthyle, b) éthyle ou c) -
       NR8R9 ;
       R8 et R9, chaque fois qu'ils apparaissent, sont, indépendamment un méthyle ou un éthyle.
  5. Un composé selon la revendication 1
    dans lequel R1 représente un a) -CH2CH2CH3, b) -C≡C-CH3 ou c) -CF3 ;
       R2 est un a) méthyle, b) éthyle, c) propyle, d) éthényle ou e) propényle ;
       R3 est un -alkyle C1-C2NR4R5 ;
       R4 et R5 sont, indépendamment l'un de l'autre, a) un méthyle ou b) un éthyle ;
       n est égal à un.
  6. Un composé selon la revendication 1
    dans lequel R1 est a) -CH2CH2CH3, b) -C≡C-CH3 ou c) -CF3 ;
       R2 représente un a) méthyle, b) éthyle, c) propyle, d) éthényle ou e) propényle ;
       R3 est un -alkyle Co-C2-hét ;
       hét est un a) morpholinyle, b) pipéridinyle ou c) pyrrolidinyle ;
       les groupes hét ci-dessus sont facultativement substitués par un ou deux groupes R6 ;
       R6 , chaque fois qu'il apparaít, est indépendamment un a) méthyle ou b) éthyle ; et
       n est égal à un.
  7. Un composé selon la revendication 1 choisi dans le groupe composé de :
    2-Phénanthrénol, 7-[[5-[(diméthylamino)méthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-2-(trifluorométhyl)-, (2R,4aS,10a R)- ;
    2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-[2-(4-morpholinyl)éthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-4a-(phénylméthyt)-2-(trifluorométhyl)-, (2R,4aS,10aR)-;
    2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-7-[[5-(1-pipéridinylméthyl)-1,2,4-oxadiazol-3-yl]méthoxy]-2-(trifluorométhyl)-, (2R,4aS,10aR)- ;
    2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-7-[[5-[2-(1-pipéridinyl)éthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-2-(1-propynyl)-, (2R,4aS,10aR)-;
    2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-2-(1-propynyl)-7-[[5-(1,2,5,6-tétrahydro-1-méthyl-3-pyridinyl)-1,2,4-oxadiazol-3-yl]méthoxy]-, (2R,4aS,10aR)- ;
    2-Phénantrénol, 7-[[5-[2-(1-azétidinyl)éthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-2-propyl-, (2R,4aS,10aR)-;
    2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(1-méthyl-3-pipéridinyl)-1,2,4-oxadiazol-3-yl]méthoxy]-4a-(phénylméthyl)-2-propyl-, (2R,4aS,10aR)-;
    2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-7-[[5-[2-(1 -pipéridinyl)éthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-2-propyl-, (2R,4aS,10aR)-;
    2-Phénanthrénol, 7-[[5-[2-(diméthylamino)éthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-2-propyl-, (2R,4aS,10aR)-;
    2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-7-[[5-(1-piperidinylméthyl)-1,2,4-oxadiazol-3-yl]méthoxy]-2-propyl-, (2R,4aS,1OaR)-;
    2-Phénanthrénol, 7-[[5-[2-(1-azétidinyl)éthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-2-(trifluorométhyl)-, (2R,4aS,10aR)- ;
    2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(1-méthyl-3-pipéridinyl)-1,2,4-oxadiazol-3-yl]méthoxy]-4a-(phénylméthyl)-2-(trifluorométhyl)-, (2R,4aS,10aR)- ; 2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-7-[[5-[2-(1-pipéridinyl)éthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-2-(trifluorométhyl)-, (2R,4aS,10aR)- ;
    2-Phénanthrénol, 7-[[5-[2-(diméthylamino)éthyl)-1,2,4-oxadiazol-3-yl]méthoxy]-1,2,3,4,4a,9,10,1 0a-octahydro-4a-(phénylméthyl)-2-(trifluorométhyl)-, (2R,4aS,10aR)- ;
    2-Phénanthrénol, 7-[[5-[2-(1 -azétidinyl)éthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-2-(1-propynyl)-, (2R,4aS,10aR)- ;
    2-Phénanthrénol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(1-méthyl-3-pipéridinyl)-1,2,4-oxadiazol-3-yl]méthoxy]-4a-(phénylméthyl)-2-(1-propynyl)-, (2R,4aS,10aR)-;
    2-Phénanthrénol, 7-[[5-[2-(diéthylamino)éthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-2-(trifluorométhyl)-, (2R,4aS,10aR)- ;
    2-Phénantrénol, 7-[[5-méthyl]-1,2,4-oxadiazol-3-yl]méthoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phénylméthyl)-2-(trifluorométhyl)-, (2R,4aS,10aR)- ;
    Phénanthrèn-2-ol, 7-(5-diméthylaminométhyl-[1,2,4]oxadiazol-3-ylméthoxy)-4a-éthyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydro-, (2R,4aR, 10aR)-;
    Phénanthrèn-2-ol, 7-[5-(2-diméthylaminoéthyl)-[1,2,4]oxadiazol-3-ylméthoxy]-4a-éthyl-2-prop-1-ynyl-1,2,3,4,43,9,10,10a-octahydro-, (2R,4aR, 10aR)-;
    Phénanthrèn-2-ol, 4a-éthyl-7-[5-(2-morpholin-4-yl-éthyl)-[1,2,4]oxadiazol-3-ylméthoxy]-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydro-, (2R,4aR, 10aR)- ; et
    Phénanthrèn-2-ol, 4a-éthyl-7-(5-pipéridin-1-ylméthyl-[1,2,4]oxadiazol-3-ylméthoxy)-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydro-, (2R,4aR, 10aR)-.
  8. Utilisation d'un composé selon la revendication 1 ou d'un sel pharmaceutiquement acceptable dudit composé, pour la préparation d'un médicament destiné au traitement de maladies ou conditions médiées par les récepteurs glucocorticoïdes chez les mammifères.
  9. L'utilisation d'un composé selon la revendication 8, dans laquelle la maladie ou condition médiée par les récepteurs glucocorticoïdes est choisie dans le groupe comprenant l'obésité, le diabète, la dépression, l'anxiété, la neurodégénération et une maladie inflammatoire.
  10. L'utilisation d'un composé selon la revendication 9, dans laquelle la maladie ou condition est l'obésité ou le diabète.
  11. Une composition pharmaceutique contenant une quantité thérapeutiquement efficace d'un composé selon la revendication 1 ou d'un sel pharmaceutiquement acceptable dudit composé, et un support, un véhicule ou un diluant pharmaceutiquement acceptable.
  12. Une composition de combinaison pharmaceutique contenant : une quantité thérapeutiquement efficace d'une composition comprenant:
    un premier composé, dit premier composé qui est un composé selon la revendication 1 ou un sel pharmaceutiquement acceptable dudit composé et
    un second composé, dit second composé qui est un agoniste β3, un agent thyromimétique, un agent modifiant le comportement alimentaire ou un antagoniste des récepteurs NPY.
  13. Une composition de combinaison pharmaceutique contenant : une quantité thérapeutiquement efficace d'une composition comprenant:
    un premier composé, dit premier composé qui est un composé selon la revendication 1, ou un sel pharmaceutiquement acceptable dudit composé et
    un second composé, dit second composé qui est un inhibiteur de l'aldose réductase, un inhibiteur de la glycogène phosphorylase, un inhibiteur de la sorbitol déshydrogénase, l'insuline, une sulfonylurée, le glipizide, le glyburide ou le chlorpropamide.
EP01308789A 2000-10-30 2001-10-16 Modulateurs des récepteurs glucocorticoides Expired - Lifetime EP1201660B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24430200P 2000-10-30 2000-10-30
US244302P 2000-10-30

Publications (2)

Publication Number Publication Date
EP1201660A1 EP1201660A1 (fr) 2002-05-02
EP1201660B1 true EP1201660B1 (fr) 2005-08-31

Family

ID=22922191

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01308789A Expired - Lifetime EP1201660B1 (fr) 2000-10-30 2001-10-16 Modulateurs des récepteurs glucocorticoides

Country Status (9)

Country Link
US (1) US6852719B2 (fr)
EP (1) EP1201660B1 (fr)
JP (1) JP2002193955A (fr)
AT (1) ATE303369T1 (fr)
BR (1) BR0104834A (fr)
CA (1) CA2360313C (fr)
DE (1) DE60113032T2 (fr)
ES (1) ES2246292T3 (fr)
MX (1) MXPA01011108A (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
JP2006508042A (ja) * 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
WO2004054587A1 (fr) * 2002-12-18 2004-07-01 University Of Zurich Traitement de troubles neuropsychiatriques
US7625921B2 (en) * 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
KR101210730B1 (ko) * 2004-07-02 2012-12-10 코어셉트 쎄라퓨틱스, 잉크. 변형된 피리미딘 글루코코티코이드 수용체 조절제
US20060154981A1 (en) * 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
CA2594943A1 (fr) * 2005-01-19 2006-07-27 Merck & Co., Inc. Inhibiteurs de la beta-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
AU2006206654A1 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of Alzheimer's disease
CA2621292C (fr) 2005-09-14 2014-05-27 Santen Pharmaceutical Co., Ltd. Derive de 1 2 dihydroquinoline a activite de fixation du recepteur des glucocorticoides glucocorticoides
MX2008011779A (es) 2006-03-14 2008-09-25 Santen Pharma Co Ltd Derivado novedoso de 1,2,3,4-tetrahidroquinoxalina con actividad de union de receptor glucocorticoide.
PL2085387T3 (pl) 2006-11-14 2013-09-30 Ayumi Pharmaceutical Corp Nowe pochodne 1,2-dihydrochinoliny zawierające jako podstawniki fenylochalkogeno-podstawioną niższą grupę alkilową oraz wprowadzoną przez ester grupę fenylową
TWI410422B (zh) * 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
CA2676670C (fr) 2007-02-02 2012-03-13 Pfizer Products Inc. Composes tricycliques et leur utilisation en tant que modulateurs des recepteurs des glucocorticoides
PL2151436T3 (pl) 2007-05-29 2013-09-30 Santen Pharmaceutical Co Ltd Nowe pochodne 1,2,3,4-tetrahydrochinoksaliny, które jako podstawnik zawierają grupę fenylową z wprowadzoną strukturą estru kwasu sulfonowego lub amidu kwasu sulfonowego i które mają aktywność wiążącą wobec receptora glukokortykoidowego
GEP20146061B (en) * 2008-05-12 2014-03-25 Santen Pharmaceutical Co Ltd Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl- 1,2-dihydroquinoline derivative having substituted oxy group
BRPI0917212A2 (pt) 2008-07-28 2015-11-10 Pfizer compostos de fenantrenona, seus usos na preparação de composições, e composições compreendendo os referidos compostos
GEP20135804B (en) * 2008-09-12 2013-04-10 Santen Pharmaceutical Co Ltd Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent
US9216221B2 (en) 2008-11-07 2015-12-22 University Of Sheffield Medicament and method of diagnosis for treating subclinical Cushing's syndrome
JP2014501785A (ja) * 2011-01-07 2014-01-23 コーセプト セラピューティクス， インコーポレイテッド ステロイドおよびグルココルチコイド受容体アンタゴニスト組合せ治療
KR101925955B1 (ko) 2011-03-18 2018-12-06 코어셉트 쎄라퓨틱스, 잉크. 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제
TW201422590A (zh) * 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (fr) 2012-12-21 2016-04-27 Abbvie Inc Modulateurs hétérocycliques des récepteurs nucléaires aux hormones
HK1252159A1 (zh) 2015-08-25 2019-05-17 参天制药株式会社 [4-(1，3，3-三甲基-2-氧代-3，4-二氢-1h-喹喔啉-7-基)苯氧基]乙基氧基化合物或其盐
US20210024628A1 (en) 2018-03-22 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
AU2019282047B2 (en) 2018-06-04 2022-06-02 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
EP4072556A4 (fr) 2019-12-11 2024-01-03 Corcept Therapeutics Incorporated Méthodes de traitement d'une prise de poids induite par médicaments antipsychotiques avec du miricorilant
IL297839A (en) 2020-05-06 2023-01-01 Corcept Therapeutics Inc Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
CN115515569A (zh) 2020-05-06 2022-12-23 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂的制剂
AU2021409656B2 (en) 2020-12-21 2025-04-10 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683091A (en) * 1967-11-13 1972-08-08 Wataru Nagata Certain phenanthrene compounds for treatment of acne
JPS50111098A (fr) 1974-02-18 1975-09-01
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
JPH06263688A (ja) 1991-09-04 1994-09-20 Otsuka Pharmaceut Factory Inc フェナンスレン誘導体
EP0676196A1 (fr) 1993-10-13 1995-10-11 Otsuka Pharmaceutical Co., Ltd. Inhibiteur de synthese de monoxyde d'azote
CA2149496C (fr) 1994-05-19 2006-12-19 Ronald Gebhard Derives du 11,21-bisphenyl-19-norpregnane
JPH0952899A (ja) 1994-09-30 1997-02-25 Tsumura & Co ロイコトリエン拮抗剤
US5693646A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
EP0903146A1 (fr) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19oxidoprogestérone (21-OH-60P) en tant qu'antiglucocorticoide
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
DE69904804T2 (de) 1998-02-13 2003-11-06 Abbott Laboratories, Abbott Park Glucocorticoid selektive entzündungshemmende mittel
JP2002527355A (ja) 1998-06-08 2002-08-27 カロ バイオ アクチェブラーグ 糖尿病の治療
WO2000006137A2 (fr) 1998-07-30 2000-02-10 Abbott Laboratories Agents selectifs de glucocorticoides
GB9816935D0 (en) 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
HUP0201243A3 (en) * 1999-04-30 2002-11-28 Pfizer Prod Inc Glucocorticoid receptor modulators, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
JP2002193955A (ja) 2002-07-10
CA2360313A1 (fr) 2002-04-30
DE60113032T2 (de) 2006-07-06
MXPA01011108A (es) 2002-06-04
EP1201660A1 (fr) 2002-05-02
BR0104834A (pt) 2002-08-20
CA2360313C (fr) 2006-12-05
ES2246292T3 (es) 2006-02-16
ATE303369T1 (de) 2005-09-15
DE60113032D1 (de) 2005-10-06
US6852719B2 (en) 2005-02-08
US20040014741A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
EP1201660B1 (fr) Modulateurs des récepteurs glucocorticoides
EP1175383B1 (fr) Glucocorticoide recepteur modulateurs
EP1201649B1 (fr) Modulateurs du récepteur corticoide
PT1521733E (pt) Moduladores do recetor de glucocorticoides
US7713989B2 (en) Glucocorticoid receptor modulators
US20070129410A1 (en) Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020827

AKX Designation fees paid

Free format text: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050831

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050831

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050831

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050831

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050831

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050831

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050831

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60113032

Country of ref document: DE

Date of ref document: 20051006

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051031

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051130

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051130

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2246292

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060222

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060601

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20060915

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20061011

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20061023

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20061031

Year of fee payment: 6

Ref country code: IT

Payment date: 20061031

Year of fee payment: 6

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20071016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080501

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20080630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071016

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20061003

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071016

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20071017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071017

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071016